Eli Lilly & Co
retatrutide
type 2 diabetes
Resolved
68days ago
Phase 3 readout · Apr 30, 2026
What's at stake
Phase 3 trial results for retatrutide in type 2 diabetes are due Apr 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“positive Phase 3 results from retatrutide in type 2 diabetes.”